Maxim Group Initiates Coverage On Mira Pharmaceuticals with Buy Rating, Announces Price Target of $3.5
Maxim Group analyst Jason McCarthy initiates coverage on Mira Pharmaceuticals (NASDAQ:MIRA) with a Buy rating and announces Price Target of $3.5.
Share
Why It Matters
A stock analyst started following Mira Pharmaceuticals and thinks it looks good. When experts believe in a company, it can mean they see something promising ahead.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.